SCHEDULE: Woodline Partners Discloses 6.8% Stake in SAB Biotherapeutics

Woodline Partners LP has filed a Schedule 13G, revealing beneficial ownership of 6.8% of SAB Biotherapeutics, Inc. common stock, including shares issuable from warrants and preferred stock.

Summary

• Woodline Partners LP, an investment adviser, has reported beneficial ownership of 5,455,355 shares of SAB Biotherapeutics, Inc. common stock.
• This holding represents 6.8% of the company's outstanding common stock as of May 6, 2026.
• The reported shares include directly held common stock, shares issuable upon conversion of Series B preferred stock underlying enrollment warrants, and shares issuable upon conversion of Series B preferred stock underlying data release warrants.
• The filing is an amendment (Amendment No. 1) to a previous Schedule 13G filing.
• Woodline Partners LP acts as the investment adviser to Woodline Master Fund LP, which holds these securities.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, indicating a significant but not overwhelming stake taken by an investment entity, suggesting confidence in the company's future prospects without immediate aggressive action.

Positives

• Significant stake acquired by an investment entity (Woodline Partners LP) indicates potential confidence in SAB Biotherapeutics' future.
• The stake includes potential future shares from warrants and preferred stock, suggesting a belief in the company's ability to convert these instruments.
• The filing is routine for a significant shareholder and does not indicate any immediate negative corporate actions.

Negatives

• The filing does not provide any new financial performance data or strategic updates, only ownership information.
• The exact value of the investment is not detailed, only the percentage of ownership.

Risks

• The filing does not explicitly mention any risks. However, the nature of warrant and preferred stock conversion carries inherent risks related to the company's stock performance and the terms of those instruments.

Future Outlook

This filing is primarily an ownership disclosure and does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Management Comments

• The filing includes a certification stating that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes. This filing by Woodline Partners LP suggests a strategic interest in SAB Biotherapeutics, potentially as a value or growth investment, within the biotechnology sector which is often characterized by significant capital requirements and long development cycles.

Comparison to Industry Standards

• The filing does not provide performance data to compare against industry standards.
• The ownership percentage of 6.8% by an investment adviser is a notable stake within the biotechnology sector, where institutional ownership can be substantial.

Stakeholder Impact

• Shareholders: The increased institutional interest may be viewed positively, potentially signaling confidence in the company's long-term prospects. However, it does not directly alter existing shareholder rights or immediate value.
• Management: The filing confirms a significant shareholder, which may influence future strategic discussions or board composition if ownership grows further.
• Creditors: No direct impact is indicated by this ownership filing.

Next Steps

• Woodline Partners LP will continue to hold and potentially manage its investment in SAB Biotherapeutics, Inc.
• Further filings may be required if Woodline Partners LP's ownership stake changes significantly.

Key Dates

Keywords

SAB Biotherapeutics, Woodline Partners LP, Schedule 13G, Beneficial Ownership, Common Stock, Preferred Stock, Warrants, Investment Adviser